Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | SCD | O00767 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL531052 | 0.99 | ACHE (0.60) | ACHEDRD2SLC6A4SCDHTR2A | |
| SCHEMBL7726651 | 0.93 | ACHE (0.55) | ACHEDRD2SLC6A4HTR2A | |
| SCHEMBL7356803 | 0.92 | ACHE (0.55) | ACHEDRD2SLC6A4SCDHTR2A | |
| Hydrochloric Acid SCHEMBL1544936 | 0.90 | ACHE (0.54) | ACHEDRD2SLC6A4SCDHTR2A | |
| Trifluoroacetic Acid SCHEMBL7453133 | 0.89 | ACHE (0.51) | ACHEDRD2SLC6A4HTR2AHTR7 | |
| SCHEMBL29688619 | 0.88 | SCD (0.51) | ACHEDRD2SLC6A4SCD | |
| SCHEMBL187372 | 0.88 | SCD (0.51) | ACHEDRD2SLC6A4SCD | |
| SCHEMBL4541441 | 0.88 | ACHE (0.58) | ACHEDRD2SLC6A4SCDHTR2A | |
| Hydrochloric Acid SCHEMBL8916694 | 0.87 | SCD (0.50) | ACHEDRD2SLC6A4SCD | |
| SCHEMBL20327895 | 0.85 | ACHE (0.56) | ACHEDRD2SLC6A4SCDHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 925 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036817-A | C-alkyl carbon glycoside and preparation method thereof | 江西师范大学 | 2026-05-15 | — | — | CN | claimed |
| CN-118852144-A | Enaminones compounds with antioxidant stress activity, preparation and application thereof | 中国医学科学院药物研究所 | 2024-10-29 | — | — | CN | claimed |
| CN-118561742-A | Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2024-08-30 | — | — | CN | claimed |
| CN-114163401-A | Preparation method and application of N-benzenesulfonyl formamidine compound | 商丘师范学院 | 2022-03-11 | — | — | CN | claimed |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | claimed |
| EP-2683717-B1 | PREPARATION OF 3-[2-[4-((6-FLUORO-1, 2-BENZISOXAZOL-3-YL)-L-PIPERIDINYL)-6, 7, 8, 9-TETRAHYDRO-9-HYDROXY-2-METHYL-4H-PYRIDO[ 1, 2-A]-PYRIMIDIN-4-ONE (PALIPERIDONE) AND PALIPERIDONE PALMITATE. | RAMAMOHAN RAO DAVULURI (IN) | 2016-05-25 | — | — | EP | claimed |
| EP-2479176-B1 | METHOD FOR PREPARATION OF ILOPERIDONE AND CRYSTALLIZATION METHOD THEREOF | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2014-09-17 | — | — | EP | claimed |
| US-20130190501-A1 | PROCESSES FOR THE PREPARATION OF 4'-[3-[4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)PIPERIDINO]PROPOXY]-3'-METHOXYACETOPHENONE AND INTERMEDIATES THEREOF | SYMED LABS LIMITED (IN) | 2013-07-25 | — | — | US | claimed |
| CN-103012387-A | Method for preparing iloperidone | UNIV ZHEJIANG | 2013-04-03 | — | — | CN | claimed |
| WO-2012153341-A1 | A PROCESS FOR THE PREPARATION OF ILOPERIDONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ARCH PHARMALABS LIMITED (IN) | 2012-11-15 | — | — | WO | claimed |
| WO-2003010166-A1 | NOVEL 2H-PYRIDAZINE-3-ONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND A PROCESS FOR THE PREPARATION OF THE ACTIVE INGREDIENT | EGIS Gyógyszergyár Rt. (HU) | 2003-02-06 | — | — | WO | claimed |
| EP-1280804-A1 | A PROCESS FOR THE PREPARATION OF ANTI-PSCHOTIC 3- 2- 4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL]ETHYL]-6,7,8,9-TETRAHYDRO-2-METHYL-4H-PYRIDO 1,2,-A]PYRIMIDIN-4-ONE | RPG Life Sciences Limited (IN) | 2003-02-05 | — | — | EP | claimed |
| WO-2001085731-A1 | A PROCESS FOR THE PREPARATION OF ANTI-PSCHOTIC 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2,-a]pyrimidin-4-one | RPG LIFE SCIENCES LIMITED (IN) | 2001-11-15 | — | — | WO | claimed |
| EP-0765323-B1 | 4-(6-FLUORO-1,2-BENZISOXAZOLYL)-1-PIPERIDINYL-PROPOXY-CHROMEN-4-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF PSYCHOSIS, SCHIZOPHRENIA AND ANXIETY | FERRER INT (ES) | 2001-07-11 | — | — | EP | claimed |
| US-5736558-A | 4-(6-fluoro-1,2-benzisoxazolyl)-1 piperidinyl-propoxy-chromen-4-one-one-derivatives, their preparation and their use in the treatment of psychosis, schizophrenia and anxiety | FERRER INTERNACIONAL, S.A. (ES) | 1998-04-07 | — | — | US | claimed |
| EP-0765323-A1 | 4-(6-FLUORO-1,2-BENZISOXAZOLYL)-1-PIPERIDINYL-PROPOXY-CHROMEN-4-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF PSYCHOSIS, SCHIZOPHRENIA AND ANXIETY | FERRER INTERNACIONAL, S.A. (ES) | 1997-04-02 | — | — | EP | claimed |
| WO-1996032389-A1 | 4-(6-FLUORO-1,2-BENZISOXAZOLYL)-1-PIPERIDINYL-PROPOXY-CHROMEN-4-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF PSYCHOSIS, SCHIZOPHRENIA AND ANXIETY | FERRER INTERNACIONAL, S.A. (ES) | 1996-10-17 | — | — | WO | claimed |
| CN-1022566-C | Process for preparing novel substituted 1-piperidinoalkylene-pyridopyrimidones or thiazolopyrimidinones | JANSSEN PHARMACEUTICA NV (BE) | 1993-10-27 | — | — | CN | claimed |
| CN-86101906-A | Process for preparing 1, 2 benzisoxazol-3-yl and 1, 2 benzisothiazol-3-yl derivatives | — | 1986-10-01 | — | — | CN | claimed |
| US-4355037-A | ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS (US) | 1982-10-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | EXOSC9, EXOSC5, EXOSC4 | ACHE 4785/4885DRD2 3540/4885SLC6A4 3953/4885 |
| US-20130190501-A1 | PROCESSES FOR THE PREPARATION OF 4'-[3-[4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)PIPERIDINO]PROPOXY]-3'-METHOXYACETOPHENONE AND INTERMEDIATES THEREOF | CYP4B1, CYP4X1, CYP3A4 | ACHE 2911/4885DRD2 2165/4885SLC6A4 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.